Oral collagen supplements may modestly ease knee osteoarthritis pain and improve joint function, but the evidence is mixed and several trials carry a high risk of bias.
For the full breakdown, see our best Collagen for Arthritis Pain guide.
A 2025 systematic review pooled 11 randomized controlled trials covering 870 people with knee osteoarthritis and found measurable improvements in pain and function. The catch: the same research keeps flagging weak trial design, short study windows, and inconsistent collagen products — so the benefit is plausible, not proven.
This matters most for knee osteoarthritis. For rheumatoid arthritis or other inflammatory joint disease, the research gathered here does not show collagen working; those are different conditions with different drivers.
What The Clinical Trials Actually Found
Across major reviews, collagen consistently beat placebo on pain scores, though the size of that edge varied. The consistency is notable; the certainty is not.
- A 2023 meta-analysis of 4 trials (507 patients) found lower pain with collagen than placebo, but every trial was rated high risk of bias.
- A 2024 systematic review of 13 trials (1,367 participants) reported significant pain reduction in 12 of 13 — yet only 4 met high methodological quality standards.
- A 2025 review (11 trials, 870 participants) reported statistically significant gains in pain and function for knee osteoarthritis.
- A broader 2026 review found collagen linked to lower osteoarthritis pain and stiffness, including 25 trials measuring self-reported pain.
The signal is steady, but trial quality is uneven, so confidence in any single number is limited.
| Review | Trials & Participants | Reported Result |
|---|---|---|
| 2023 meta-analysis | 4 trials, 507 patients | Lower pain vs. placebo; all trials high risk of bias |
| 2024 systematic review | 13 trials, 1,367 participants | Pain reduced in 12 of 13; only 4 rated high quality |
| 2025 systematic review | 11 trials, 870 participants | Significant pain and function improvement |
| 2026 broader review | 25 RCTs for self-reported pain | Lower osteoarthritis pain and stiffness |
| 2018 meta-analysis | Earlier pooled data | WOMAC and VAS improved overall; subscores unclear |
| 2023 meta-analysis (safety) | 507 patients | No significant rise in adverse events vs. placebo |
How Big Is The Benefit, Really?
Effect sizes are small to moderate — enough to notice, not enough to replace other treatment. The 2025 review reported pooled pain improvement of MD -13.63 and function improvement of MD -6.46 favoring collagen. The 2023 meta-analysis put pain improvement at a standardized mean difference of -0.58 versus placebo. A 2018 meta-analysis saw overall WOMAC and VAS gains but could not clearly separate pain and function.
This might take the edge off, not turn arthritis off. Reading it as a cure oversells it; reading it as useless undersells the trials.
Collagen is not uniform, which complicates every comparison. Studies use different types — peptides, hydrolyzed collagen, type I and type III preparations — at different doses and durations. The 2023 review focused on collagen peptides; the 2026 review noted benefits with hydrolyzed and type II formulations in knee osteoarthritis, but flagged the evidence as heterogeneous. If weighing specific products, a tested collagen for arthritis pain roundup can help you compare what is on the shelf.
Is Collagen Safe To Take?
Safety looked clean, with no meaningful jump in side effects versus placebo. The 2023 meta-analysis found no significant difference in adverse events, though certainty was very low. The 2026 review described tolerability as good and side effects as minimal.
Two cautions: “no significant difference” in a small, biased trial set is not a guarantee, so run any new supplement past your doctor — especially alongside blood thinners or other medication. And safety evidence cannot rescue weak efficacy evidence. A supplement can be harmless and still not do much.
Should You Try It For Arthritis?
Oral collagen may modestly improve knee osteoarthritis pain and function, with good tolerability and low risk of side effects. It is reasonable to discuss with your doctor as part of a broader plan — not a replacement for prescribed treatment.
Weigh it honestly: benefits are real but small; trial quality is uneven; evidence leans toward knee osteoarthritis, not all forms of arthritis. The 2024 review concluded better randomized trials are needed before certainty. If it helps and your doctor signs off, that is enough reason to continue. If it does nothing after a few months, you have lost little.
FAQs
How long until collagen might help joint pain?
The trials ran for varying durations, and none of the summaries establish a firm timeline. Because study windows were short, the long-term picture is unclear. Give it a few months and track your symptoms rather than expecting overnight change.
Is collagen helpful for rheumatoid arthritis?
The research gathered here does not establish collagen as effective for rheumatoid arthritis pain. The strongest evidence is for osteoarthritis, especially of the knee. Rheumatoid arthritis is a different, inflammatory condition, and osteoarthritis findings should not be assumed to apply. Talk to your rheumatologist before adding any supplement.
What type of collagen do the studies use?
Studies use different forms — collagen peptides, hydrolyzed collagen, and type I or type III preparations. The 2026 review noted benefits with hydrolyzed and type II formulations in knee osteoarthritis. Because products are not uniform, results cannot be treated as one interchangeable finding across every supplement.
References & Sources
- PubMed. “Collagen Supplementation for Knee Osteoarthritis: A Systematic Review” Supports the 2025 pooled pain and function improvements in knee osteoarthritis.
- PubMed. “Collagen Peptides and Osteoarthritis: A Meta-Analysis” Supports the 2023 pain-reduction finding and the high risk of bias across four trials.
- PMC. “Collagen Supplementation and Osteoarthritis Outcomes” Supports the 2026 review of lower pain and stiffness across multiple randomized trials and its tolerability notes.
